• Publié par : Fabienne LETELLIER-NICOLAS
  • Imprimer cette page


2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003



  • Amiot, L., Le Friec, G., Sebti, Y., Drenou, B., Pangault, C., Guilloux, V., Leleu, X., Bernard, M., Facon, T., Fauchet, R., HLA-G and lymphoproliferative disorders. Semin Cancer Biol. 2003. 13: 379-385.
  • Bouet-Toussaint, F., Patard, J.J., Gervais, A., Genetet, N., de La Pintière, C.T., Rioux-Leclercq, N., Toutirais, O., Thirouard, A. S., Ramée, M. P., Catros-Quemener, V., Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use. Cancer Immunol Immunother. 2003. 52: 699-707.
  • Catros-Quemener, V., Bouet, F., Genetet, N., Antitumor immunity and cellular cancer therapies. Med Sci (Paris). 2003. 19: 43-53.
  • Creput, C., Le Friec, G., Bahri, R., Amiot, L., Charpentier, B., Carosella, E., Rouas-Freiss, N., Durrbach, A., Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol. 2003. 64: 1033-1038. 
  • Le Friec, G., Laupeze, B., Fardel, O., Sebti, Y., Pangault, C., Guilloux, V., Beauplet, A., Fauchet, R., Amiot, L., Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol. 2003. 64: 752-761. 
  • Sebti, Y., Le Friec, G., Pangault, C., Gros, F., Drenou, B., Guilloux, V., Bernard, M., Lamy, T., Fauchet, R., Amiot, L., Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003. 64: 1093-1101.
  • Toutirais, O., Chartier, P., Dubois, D., Bouet, F., Levêque, J., Catros-Quemener, V., Genetet, N., Constitutive expression of TGF-β1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw. 2003. 14: 246-255.